Proviron should be cautioned that antiretroviral therapy does not prevent the risk of transmission of HIV through blood or during sexual intercourse, and therefore care should be taken. Diabetes mellitus / hyperglycemia The treatment of HIV protease inhibitors in some HIV-infected patients had hyperglycemia, appearance or worsening of diabetes existing diabetes. In some cases, there diabetic ketoacidosis.
A causal relationship between treatment HIV protease inhibitors and these cases has not been established. Hemophilia patients with hemophilia type A and B during treatment with HIV protease inhibitors were observed bleeding, including spontaneous skin bleeding and hemarthrosis, some of these patients required administration of clotting factor VIII. In most cases, treatment of HIV protease inhibitors was continued or resumed after the break. A causal relationship between treatment HIV protease inhibitors and these cases are not established. Fat redistributionThere have been isolated cases of redistribution of fat, which manifested obesity on the central type, increased fat in dorsotservikalnoy zone ( “buffalo hump”), a weight loss of limbs and face , breast enlargement, “cushingoid face.”
A causal relationship between treatment HIV protease inhibitors and these cases has not been established. Immune reconstitution syndrome in HIV-infected patients at the start of combination antiretroviral therapy may be signs of an inflammatory reaction in response to asymptomatic or residual opportunistic infections (caused by Mycobacterium avium, cytomegalovirus, Pneumocystis jiroveci or tuberculosis). May require examination and appropriate treatment. Liver failure provironis metabolized primarily in the liver, so patients with hepatic failure patients the drug should be used with caution because of a possible increase in its concentration.
In patients with viral hepatitis B or C or marked prior to treatment elevated transaminase activity there is a risk of further increasing transaminases. Hyperbilirubinemia patients receiving , there have been cases of reversible increase in indirect (free) bilirubin related to inhibition of UDP-glucuronosyltransferase (UGT). It should be noted that the increase in transaminases, have been reported with elevated bilirubin in patients receiving Reyataz, can be caused by other diseases, is also accompanied by hyperbilirubinemia. No long-term about the application of safety data in patients with long-lasting levels of bilirubin, more than 5 times higher than normal . If jaundice or yellowing of the sclera are patient cosmetic problem, you might consider the possibility of appointing an alternate drug antnretrovirusnoy therapy.
Drug R reduction is not recommended due to lack of data on the efficacy of reduced doses. Lengthening of the interval provironcan lengthen the interval in some patients. Caution should be exercised when using the drug in patients with cardiac conduction disturbances. Caution must be exercised when applying the drug combined with drugs that prolong the interval (such as atenolol, diltiazem, verapamil). Rash maculopapular rash, usually mild to moderate, may occur within the first 3 weeks of starting therapy with . In most patients, rash disappeared within 2 weeks with continued therapy. Use of the drug should be discontinued if severe rash development. Nephrolithiasis during post-marketing study of the safety of the drug patients have been cases of nephrolithiasis. If you have symptoms of nephrolithiasis must temporarily interrupt therapy or completely stop taking the drug.